<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002033.pub2" GROUP_ID="GYNAECA" ID="493200012710350467" MERGED_FROM="" MODIFIED="2017-03-08 11:44:07 +0000" MODIFIED_BY="Joanne Platt" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;extensively peer reviewed for JAMA, therefore not to be peer reviewed by CGCCRG (CW decision)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-08 11:42:58 +0000" NOTES_MODIFIED_BY="Joanne Platt" REVIEW_NO="C009" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2017-03-08 11:44:02 +0000" MODIFIED_BY="Joanne Platt">
<TITLE>Nystatin prophylaxis and treatment in severely immunodepressed patients</TITLE>
<CONTACT MODIFIED="2017-03-08 11:44:02 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-03-08 11:44:02 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-03-08 11:42:31 +0000" MODIFIED_BY="Joanne Platt">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-08 11:42:58 +0000" MODIFIED_BY="Joanne Platt">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-03-08 11:42:58 +0000" MODIFIED_BY="Joanne Platt">
<DATE DAY="8" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Intervention no longer in general use.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-21 14:28:50 +0100" MODIFIED_BY="Tracey Harrison">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-21 14:28:50 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>No new trials identified for inclusion</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-21 14:28:50 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Literature searches updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 11:57:16 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="14" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Review updated with new search details. No new studies were identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 11:57:16 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="18" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Searches re-run July 2011.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:30:48 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:30:42 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>New studies found and included or excluded:One new outcome added (harms), one excluded trial added (Epstein)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:38:51 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="29" MONTH="7" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rigshospitalet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>JASCHA-fonden</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Nordic Council of Ministers</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Swedish Society of Medicine</NAME>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-03 12:15:38 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2014-09-03 12:00:10 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2014-09-03 12:00:08 +0100" MODIFIED_BY="Clare Jess">Prevention and treatment of fungal infections with nystatin in severely immunodepressed patients</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-03 12:00:10 +0100" MODIFIED_BY="Clare Jess">
<P>People on chemotherapy for cancer, receiving a transplant or with AIDS are at risk of fungal infections. These infections can be life-threatening, especially when they spread throughout the body. Nystatin is sometimes given as a routine preventive measure or as treatment in these patients. The review found that nystatin was no better than placebo (no treatment).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-03 12:00:01 +0100" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2014-09-03 11:59:29 +0100" MODIFIED_BY="Clare Jess">
<P>Nystatin is sometimes used prophylactically in patients with severe immunodeficiency or in the treatment of fungal infection in such patients, although its effect seems to be equivocal.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To study whether nystatin decreases morbidity and mortality when given prophylactically or therapeutically to patients with severe immunodeficiency.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-03 11:59:30 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials comparing nystatin with placebo, an untreated control group, fluconazole or amphotericin B.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-03 11:59:43 +0100" MODIFIED_BY="Clare Jess">
<P>Data on mortality, invasive fungal infection and colonisation were independently extracted by both authors. A random-effects model was used unless the P value was greater than 0.10 for the test of heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-03 11:59:57 +0100" MODIFIED_BY="Clare Jess">
<P>We included 14 trials (1569 patients). The drugs were given prophylactically in 12 trials and as treatment in two. Eleven trials were in acute leukaemia, solid cancer, or bone marrow recipients; one in liver transplant patients; one in critically ill surgical and trauma patients; and one in AIDS patients. Nystatin was compared with placebo in three trials, with fluconazole in 10, and amphotericin B in one; the dose varied from 0.8 MIE to 72 MIE daily and was 2 mg/kg/d in a liposomal formulation. The effect of nystatin was similar to that of placebo on fungal colonisation (relative risk (RR) 0.85, 95% confidence interval (CI) 0.65 to 1.13). There was no statistically significant difference between fluconazole and nystatin on mortality (RR 0.75, 95% CI 0.54 to 1.03) whereas fluconazole was more effective in preventing invasive fungal infection (RR 0.40, 95% CI 0.17 to 0.93) and colonisation (RR 0.50, 95% CI 0.36 to 0.68). There were no proven fungal infections in a small trial that compared amphotericin B with liposomal nystatin. The results were very similar if the three studies that were not performed in cancer patients were excluded. For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-03 12:00:01 +0100" MODIFIED_BY="Clare Jess">
<P>Nystatin cannot be recommended for prophylaxis or the treatment of Candida infections in immunodepressed patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-03 12:15:38 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2014-09-03 12:00:12 +0100" MODIFIED_BY="Clare Jess">
<P>Nystatin is often used for treatment of oral candidiasis in otherwise healthy patients, for example in patients with candidiasis after antibiotic therapy or in patients with denture stomatitis. The drug is also sometimes used prophylactically in patients with severe immunodeficiency, for example in patients undergoing antileukaemic chemotherapy or bone marrow transplantation or in patients with AIDS. We reviewed the relevant clinical trials in patients with severe immunodeficiency.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To study whether nystatin decreases morbidity and mortality when given prophylactically or therapeutically to patients with severe immunodeficiency.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-03 12:15:30 +0100" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2014-09-03 12:00:19 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES MODIFIED="2014-09-03 12:00:14 +0100" MODIFIED_BY="Clare Jess">
<P>All randomised trials, irrespective of language, which compared nystatin with placebo, an untreated control group, fluconazole or amphotericin B were eligible. Fluconazole and amphotericin B were chosen as active comparators as in a previous Cochrane review of placebo controlled trials (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>) they appeared to be the most effective antifungal agents.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-09-03 12:00:15 +0100" MODIFIED_BY="Clare Jess">
<P>Patients with severe immunodeficiency predisposing to fungal infection, for example patients undergoing antileukaemic chemotherapy or bone marrow transplantation and patients with AIDS.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-03 12:00:18 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: nystatin. Control: placebo, no treatment, fluconazole or amphotericin B.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-03 12:00:19 +0100" MODIFIED_BY="Clare Jess">
<UL>
<LI>Mortality</LI>
<LI>Invasive fungal infection (defined as a positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue involvement)</LI>
<LI>Colonisation</LI>
<LI>Harms</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-03 12:00:21 +0100" MODIFIED_BY="Clare Jess">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-03 12:00:20 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
<P>The search strategy used is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. </P>
<P>The search strategies have been developed and executed by the author team.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-03 12:00:21 +0100" MODIFIED_BY="Clare Jess">
<P>This has not been carried out since 2007 as we have not found it worthwhile.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-03 12:15:30 +0100" MODIFIED_BY="Clare Jess">
<DATA_EXTRACTION MODIFIED="2014-09-03 12:00:27 +0100" MODIFIED_BY="Clare Jess">
<P>Decisions on which trials to include and which variables to use when a number of options were available for the same outcome were based on the methods sections of the trials. Details on diagnosis, drug, dose, randomisation and blinding methods, number of randomised patients, number of patients excluded from analysis, deaths, invasive fungal infections and colonisation were independently extracted by both authors; differences in the data extracted were resolved by consensus.</P>
<P>We defined invasive fungal infection as a positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue infection (<LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>). We excluded cases of oropharyngeal and vulvovaginal candidiasis, skin infections, Candida in the urine and vaguely described infections.</P>
</DATA_EXTRACTION>
<DATA_SYNTHESIS MODIFIED="2014-09-03 12:15:30 +0100" MODIFIED_BY="Clare Jess">
<P>The outcomes were meta-analysed as relative risks with the Mantel-Haenszel technique. Since heterogeneity of the studies was expected because of various designs, diagnoses, drugs, doses and routes of administration, and criteria for fungal invasion and colonisation a random-effects model was used. A fixed-effect model analysis was preferred, however, if the P value was greater than 0.10 for the test of heterogeneity. Ninety-five per cent confidence intervals were presented.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-03 12:15:38 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2014-09-03 12:02:35 +0100" MODIFIED_BY="Clare Jess">
<P>We identified 18 potentially relevant reports. Four were subsequently excluded. A trial in which only 12 patients received nystatin failed due to serious problems with compliance (<LINK REF="STD-Hoppe-1995" TYPE="STUDY">Hoppe 1995</LINK>); another reported only the number of 'Candida-free' days (which was 18 on both nystatin and on placebo) (<LINK REF="STD-Williams-1977" TYPE="STUDY">Williams 1977</LINK>); the third report was a duplicate publication (<LINK REF="STD-Ellis-1994" TYPE="STUDY">Ellis 1994</LINK>); and in the fourth trial, which compared nystatin with amphotericin B (<LINK REF="STD-Epstein-2004" TYPE="STUDY">Epstein 2004</LINK>), all 40 patients received systemic fluconazole 200 mg/d, which is an effective treatment. Of the 14 included trials 3 were published as abstracts only (<LINK REF="STD-Feusner-1994" TYPE="STUDY">Feusner 1994</LINK>; <LINK REF="STD-Powles-1999" TYPE="STUDY">Powles 1999</LINK>; <LINK REF="STD-Tian-1997" TYPE="STUDY">Tian 1997</LINK>).</P>
<P>The drugs were given prophylactically in 12 trials and as treatment in 2 (<LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>; <LINK REF="STD-Pons-1997" TYPE="STUDY">Pons 1997</LINK>). Acute leukaemia was the most common disease in eight trials; two trials concerned exclusively (<LINK REF="STD-Feusner-1994" TYPE="STUDY">Feusner 1994</LINK>) or mainly (<LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>) patients with cancer, one mainly patients receiving a bone marrow transplant (<LINK REF="STD-Powles-1999" TYPE="STUDY">Powles 1999</LINK>), one patients receiving a liver transplant (<LINK REF="STD-Lumbreras-1996" TYPE="STUDY">Lumbreras 1996</LINK>), one critically ill surgical and trauma patients (<LINK REF="STD-Savino-1994" TYPE="STUDY">Savino 1994</LINK>), and one AIDS patients (<LINK REF="STD-Pons-1997" TYPE="STUDY">Pons 1997</LINK>). Nystatin was compared with placebo or no treatment in 3 trials, with fluconazole in 10, and with amphotericin B in one; all drugs were given orally apart from the amphotericin B trial (<LINK REF="STD-Powles-1999" TYPE="STUDY">Powles 1999</LINK>). The daily dose of nystatin in adults varied from 0.8 MIE to 72 MIE daily, and was 2 mg/kg/d in a liposomal formulation. In three trials the participants were children (<LINK REF="STD-Feusner-1994" TYPE="STUDY">Feusner 1994</LINK>; <LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>; <LINK REF="STD-Groll-1997" TYPE="STUDY">Groll 1997</LINK>). Length of follow-up was stated in only three trials (<LINK REF="STD-Ellis-1994" TYPE="STUDY">Ellis 1994</LINK>; <LINK REF="STD-Lumbreras-1996" TYPE="STUDY">Lumbreras 1996</LINK>; <LINK REF="STD-Powles-1999" TYPE="STUDY">Powles 1999</LINK>). Although one of the trials was described as a two-armed study (<LINK REF="STD-Groll-1997" TYPE="STUDY">Groll 1997</LINK>), 18 of the patients were also included in a report of a three-armed study (<LINK REF="REF-Ninane-1994" TYPE="REFERENCE">Ninane 1994</LINK>). We have previously drawn attention to this curious discrepancy but it has not been explained (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>).</P>
<P>For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-03 12:02:41 +0100" MODIFIED_BY="Clare Jess">
<P>We adopted broad quality assessment criteria and considered the risk of bias to be be low if the randomisation method was concealed, for example if central randomisation, use of sealed envelopes, a code provided by a pharmacy or a company was described; and if the generation of the allocation sequence was adequate (for example random numbers) and the trial was placebo controlled and blinded. Concealment of treatment allocation was reported in three trials (<LINK REF="STD-Ellis-1994" TYPE="STUDY">Ellis 1994</LINK>; <LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>; <LINK REF="STD-Savino-1994" TYPE="STUDY">Savino 1994</LINK>). Blinding was reported in five trials; the control group received saline in one trial (<LINK REF="STD-Epstein-1992" TYPE="STUDY">Epstein 1992</LINK>), the double-dummy technique was used in one trial (<LINK REF="STD-Young-1999" TYPE="STUDY">Young 1999</LINK>), and the assessors were blinded in three trials (<LINK REF="STD-Ellis-1994" TYPE="STUDY">Ellis 1994</LINK>; <LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>; <LINK REF="STD-Pons-1997" TYPE="STUDY">Pons 1997</LINK>). Losses to follow-up and exclusions were reasonably low apart from one trial (<LINK REF="STD-Young-1999" TYPE="STUDY">Young 1999</LINK>) where the only reliable data were those for mortality (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-03 12:15:38 +0100" MODIFIED_BY="Clare Jess">
<P>None of the three placebo-controlled trials reported on deaths or on invasive fungal infection according to our criteria. One trial reported five cases of sepsis on nystatin and two on placebo but the definition of sepsis included positive cultures from at least three sites (<LINK REF="STD-Savino-1994" TYPE="STUDY">Savino 1994</LINK>). The effect of nystatin was similar to that of placebo on fungal colonisation; the total number of colonisations on nystatin was 53 out of 164 patients while it was 57 out of 147 on placebo (relative risk (RR) 0.85, 95% confidence interval (CI) 0.65 to 1.13).</P>
<P>There was no statistically significant difference between fluconazole and nystatin on mortality (RR 0.75, 95% CI 0.54 to 1.03) whereas fluconazole was considerably more effective in preventing invasive fungal infection (RR 0.40, 95% CI 0.17 to 0.93) and colonisation (RR 0.50, 95% CI 0.36 to 0.68). There was marked heterogeneity for colonisation (P value &lt; 0.001), which was driven by an unusually large effect of fluconazole in one of the two treatment trials in which the patients had oropharyngeal thrush (<LINK REF="STD-Flynn-1995" TYPE="STUDY">Flynn 1995</LINK>) and a very small effect in one of the prophylactic trials (<LINK REF="STD-Groll-1997" TYPE="STUDY">Groll 1997</LINK>). The heterogeneity was probably caused by the lack of a consistent definition of colonisation. If these two studies were excluded the heterogeneity disappeared whereas the RR was virtually the same as before (RR 0.48, 95% CI 0.39 to 0.58). The results were also similar for all three outcomes if the studies that were not performed in cancer patients were excluded. There were no proven fungal infections in a small trial that compared amphotericin B with liposomal nystatin (4 out of 15 versus 2 out of 16 patients died) (<LINK REF="STD-Powles-1999" TYPE="STUDY">Powles 1999</LINK>).</P>
<P>The results were similar for the trials with adequate concealment of allocation, but the power was low for a comparison with those trials that did not provide information on the randomisation method.</P>
<P>The reporting of harms was variable from trial to trial, and some trials reported no data at all (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Treatment discontinuations were most commonly caused by nausea, vomiting, and liver enzyme increases; and oral administration of nystatin was described as difficult in two trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-03 12:03:52 +0100" MODIFIED_BY="Clare Jess">
<P>Nystatin is an old drug which is still frequently used for the prophylaxis and treatment of Candida infections. However, it is widely recognized as being a relatively ineffective drug. Nystatin is almost insoluble and it is not recommended for use in cancer patients with neutropenia (<LINK REF="REF-Working-Party-1995" TYPE="REFERENCE">Working Party 1995</LINK>). We could confirm this recommendation, at least in patients with severe immunodeficiency, which was the type of patients we included in this review. Nystatin was no better than placebo and this finding is strengthened by the fact that the difference between fluconazole and nystatin was very similar to the difference between fluconazole and placebo, which we have reported on previously (<LINK REF="REF-G_x00f8_tzsche-1997" TYPE="REFERENCE">Gøtzsche 1997</LINK>; <LINK REF="REF-G_x00f8_tzsche-2002" TYPE="REFERENCE">Gøtzsche 2002</LINK>). Whether nystatin is effective in patients who are not immunodepressed is a different matter that needs a separate review.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-03 12:03:55 +0100" MODIFIED_BY="Clare Jess">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-03 12:03:54 +0100" MODIFIED_BY="Clare Jess">
<P>The effect of nystatin given orally to immunodepressed patients was no better than that of placebo, whereas it was inferior to the effect of fluconazole. Nystatin cannot be recommended for prophylaxis or treatment of Candida infections in immunodepressed patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-03 12:03:55 +0100" MODIFIED_BY="Clare Jess">
<P>There seems to be little scope for further trials of nystatin given orally to immunodepressed patients since more effective antifungal agents exist, and since the effect of nystatin was at placebo level.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-31 10:24:51 +0100" MODIFIED_BY="Clare Jess">
<P>We wish to thank our funders for the research grants which made this review possible.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological, Neuro-oncology, Orphan Cancer Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-07-30 12:04:03 +0100" MODIFIED_BY="Tracey Bishop">
<P>Peter C Gøtzsche - nothing to declare<BR/>Helle Krogh Johansen - nothing to declare</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>HKJ wrote the draft meta-analysis protocol, HKJ and PG contributed equally to selection of trials, data extraction and writing of the manuscript. Guarantors: both authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-03 12:03:57 +0100" MODIFIED_BY="Clare Jess">
<P>There was no separate protocol for this review as we were asked by the editors of JAMA to do an additional meta-analysis on nystatin when we published our review on fluconazole (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>); we therefore based the current review as part of the protocol for the fluconazole review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-08 11:44:07 +0000" MODIFIED_BY="Joanne Platt">
<STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Buchanan-1985" MODIFIED="2014-07-31 15:40:58 +0100" MODIFIED_BY="Clare Jess" NAME="Buchanan 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-07-31 15:40:58 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan AG, Riben PD, Rayner EN, Parker SE, Ronald AR, Louie TJ</AU>
<TI>Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome</TI>
<SO>Clinical and Investigative Medicine</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>139-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405832"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egger-1995" MODIFIED="2014-07-31 15:41:02 +0100" MODIFIED_BY="Clare Jess" NAME="Egger 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-31 15:41:02 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Egger T, Gratwohl A, Tichelli A, Uhr M, Stebler Gysi C, Passweg J et al</AU>
<TI>Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>139-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405834"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1994" MODIFIED="2014-07-31 15:42:19 +0100" MODIFIED_BY="Clare Jess" NAME="Ellis 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:42:19 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D et al</AU>
<TI>Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>3-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405837"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-30 12:07:51 +0100" MODIFIED_BY="Tracey Bishop" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis ME, Qadri SM, Spence D, Halim MA, Ernst P, Clink H et al</AU>
<TI>The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1994</YR>
<VL>33</VL>
<PG>1223-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405838"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405836"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1992" MODIFIED="2014-07-31 15:42:23 +0100" MODIFIED_BY="Clare Jess" NAME="Epstein 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-07-31 15:42:23 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Vickars L, Spinelli J, Reece D</AU>
<TI>Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1992</YR>
<VL>73</VL>
<PG>682-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405839"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feusner-1994" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NAME="Feusner 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Feusner J, Robinson P, Seibel N, Reaman G, Waskerwitz M, and Thompson C. Fluconazole (FLU) vs Nystatin (NYS) for the prevention of fungal infection in neutropenic children receiving cytotoxic chemotherapy . Proc-Annu-Meet-Am-Soc-Clin-Oncol 1994; 13:ABS. A1533.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:04:24 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feusner J, Robinson P, Seibel N, Reaman G, Waskerwitz M, Thompson C</AU>
<TI>Fluconazole (FLU) vs nystatin (NYS) for the prevention of fungal infection in neutropenic children receiving cytotoxic chemotherapy</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>444 (Abstract A1533)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405842"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405841"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-1995" MODIFIED="2014-07-31 15:42:30 +0100" MODIFIED_BY="Clare Jess" NAME="Flynn 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-31 15:42:30 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA et al</AU>
<TI>Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group</TI>
<SO>The Journal of Paediatrics</SO>
<YR>1995</YR>
<VL>127</VL>
<PG>322-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405844"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405843"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groll-1997" MODIFIED="2014-07-31 15:42:33 +0100" MODIFIED_BY="Clare Jess" NAME="Groll 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-31 15:42:33 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Groll AH, Just-Nuebling G, Kurz M, Mueller C, Nowak-Goettl U, Schwabe D et al</AU>
<TI>Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>855-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405846"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405845"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lumbreras-1996" MODIFIED="2014-07-31 15:42:37 +0100" MODIFIED_BY="Clare Jess" NAME="Lumbreras 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-07-31 15:42:37 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrion VS, Barrios C et al</AU>
<TI>Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<PG>583-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405848"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405847"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pons-1997" MODIFIED="2014-07-31 15:42:41 +0100" MODIFIED_BY="Clare Jess" NAME="Pons 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-07-31 15:42:41 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pons V, Greenspan D, Lozada-Nur F, McPhail L, Gallant JR, Tunkel A et al</AU>
<TI>Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>1204-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405849"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powles-1999" MODIFIED="2014-07-31 15:42:45 +0100" MODIFIED_BY="Clare Jess" NAME="Powles 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-31 15:42:45 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Powles R, Kulkarni S, Treleaven J, Hobbs K, Sirohi B, Bhagwati N et al</AU>
<TI>Phase III randomized trial of Nyotran (liposomal nystatin) or amphotericin B for the empiric antifungal therapy in febrile neutropenic patients [abstract]. 41st Annual Meeting of the American Society of Hematology</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>94 (10 Suppl 1)</VL>
<PG>342a</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savino-1994" MODIFIED="2014-07-31 15:42:48 +0100" MODIFIED_BY="Clare Jess" NAME="Savino 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:42:48 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L</AU>
<TI>Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients</TI>
<SO>The Journal of Trauma</SO>
<YR>1994</YR>
<VL>36</VL>
<PG>20-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405854"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405853"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-1997" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NAME="Tian 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Tian D, Jian H, Cui X et al</AU>
<TI>Prospective study of fluconazole in the prevention of fungal infections in neutropenic patients with acute leukemia and non-Hodgkins lymphoma</TI>
<SO>20th International Congress of Chemotherapy, June 29 to July 3 1997, Sydney, Australia</SO>
<YR>1997</YR>
<PG>87 abstract no 3246</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405856"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405855"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Delden-1995" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NAME="van Delden 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Delden C, Lew DP, Chapuis B, Rohner P, Hirschel B</AU>
<TI>Antifungal prophylaxis in severely neutropenic patients: How much fluconazole is necessary?</TI>
<SO>Journal of Clinical Microbiology and Infection</SO>
<YR>1995</YR>
<VL>1(1)</VL>
<PG>24-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405858"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405857"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1999" MODIFIED="2014-07-31 15:43:00 +0100" MODIFIED_BY="Clare Jess" NAME="Young 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-31 15:43:00 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Young GA, Bosly A, Gibbs DL, Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group. Eur J Cancer 1999; 35(8):1208-13.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:43:00 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young GA, Bosly A, Gibbs DL, Durrant S</AU>
<TI>A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. Antifungal Prophylaxis Study Group</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1208-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405860"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405859"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Carpentieri-1978" NAME="Carpentieri 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpentieri U, Haggard ME, Lockhart LH, Gustavson LP, Box QT, West EF</AU>
<TI>Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia</TI>
<SO>The Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<PG>593-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405862"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405861"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeGregorio-1982" NAME="DeGregorio 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeGregorio MW, Lee WM, Ries CA</AU>
<TI>Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>50</VL>
<PG>2780-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405864"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405863"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-2004" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NAME="Epstein 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Truelove EL, Hanson-Huggins K, Mancl LA, Chen A, Press OW et al</AU>
<TI>Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2004</YR>
<VL>12(7)</VL>
<PG>517-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405866"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405865"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoppe-1995" NAME="Hoppe 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoppe JE, Friess D, Niethammer D</AU>
<TI>Orointestinal yeast colonization of paediatric oncologic patients during antifungal prophylaxis: results of quantitative culture and Candida serology and comparison of three polyenes</TI>
<SO>Mycoses</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>41-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405868"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405867"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1977" NAME="Williams 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams C, Whitehouse JM, Lister TA, Wrigley PF</AU>
<TI>Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1977</YR>
<VL>3</VL>
<PG>275-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405869"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-09-29 11:08:28 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_REFERENCES MODIFIED="2011-09-29 11:07:20 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-G_x00f8_tzsche-1997" NAME="Gøtzsche 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002" MODIFIED="2011-09-29 11:07:20 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2002" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Routine versus selective antifungal administration for control of fungal infections in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:07:20 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:07:20 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ninane-1994" NAME="Ninane 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ninane J</AU>
<TI>A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>330-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Working-Party-1995" NAME="Working Party 1995" TYPE="JOURNAL_ARTICLE">
<AU>Working Party of the British Society for Antimicrobial Chemotherapy</AU>
<TI>Antifungal drug chemotherapy. Antifungal drug susceptibility testing</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-09-29 11:08:28 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-G_x00f8_tzsche-2001" MODIFIED="2011-09-29 11:08:28 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2001" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Nystatin prophylaxis and treatment in severely immunodepressed patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:08:24 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:08:24 +0100" MODIFIED_BY="Gail Quinn" TYPE="DOI" VALUE="10.1002/14651858.CD002033"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-1999" NAME="Johansen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>1752-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:01 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Buchanan-1985">
<CHAR_METHODS MODIFIED="2014-09-03 12:03:59 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:00 +0100" MODIFIED_BY="Clare Jess">
<P>78 patients with acute leukaemia, prophylactic<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:00 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: nystatin suspension 1 MIE x 6<BR/>Control: no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:01 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:03 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Egger-1995">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:01 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:01 +0100" MODIFIED_BY="Clare Jess">
<P>90 patients with acute leukaemia, prophylactic<BR/>Excluded: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:02 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 400 mg orally or iv once daily<BR/>Control: nystatin suspension 24 MIE x 3 and miconazole inhalations x 3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:03 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:04 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Ellis-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:03 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated code at pharmacy<BR/>Blinding: observer and analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:03 +0100" MODIFIED_BY="Clare Jess">
<P>94 patients with acute leukaemia, prophylactic<BR/>Excluded: 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:04 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 200 mg orally once daily<BR/>Control: mouthwash with nystatin 0.5 MIE, benadryl elixir and cepacol x 4 and clotrimazole troches 10 mg x 2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:04 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:06 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Epstein-1992">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:04 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: saline as control treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:05 +0100" MODIFIED_BY="Clare Jess">
<P>99 patients with acute leukaemia, prophylactic<BR/>Excluded: 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:05 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: nystatin suspension 1.5 MIE x 4<BR/>Control: saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:05 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Oral mucositis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:06 +0100" MODIFIED_BY="Clare Jess">
<P>Factorial design</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Feusner-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:06 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:06 +0100" MODIFIED_BY="Clare Jess">
<P>178 children with neutropenia after chemotherapy, prophylactic<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 6 mg/kg/d<BR/>Control: nystatin 0.4 MIE x 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Published as abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Flynn-1995">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated code held by pharmacist<BR/>Blinding: observer<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>186 children with immunodeficiency (92 cancer, 64 HIV, 30 immunosuppressive disorder and/or therapy) and oral candidiasis, treatment<BR/>Excluded: 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole suspension 2 mg/kg/d<BR/>Control: nystatin suspension 0.4 MIE x 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Deaths<BR/>Clinical symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Groll-1997">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>60 children with acute leukaemia, prophylactic<BR/>Excluded: 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole suspension 3 mg/kg/d<BR/>Control: nystatin suspension 0.05 MIE/kg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Although this is described as a two-armed study, 18 of the patients were also included in a report of a three-armed study (Ninane 1994). This discrepancy has not been explained</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Lumbreras-1996">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>143 patients with a liver transplant, prophylactic<BR/>Excluded: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole capsule 100 mg daily<BR/>Control: nystatin suspension 1 MIE x 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Pons-1997">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: observer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>167 patients with AIDS and oropharyngeal candidiasis, treatment<BR/>Excluded: 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole suspension 100 mg daily<BR/>Control: nystatin suspension 0.5 MIE x 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Deaths<BR/>Clinical cure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Powles-1999">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>31 cancer patients with neutropenia, mostly bone marrow recipients, empiric<BR/>Excluded: four patients were "non-evaluable"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B 0.8 mg/kg/d iv over 4 h<BR/>Control: liposomal nystatin 2 mg/kg/d i.v. over 2 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Normalisation of temperature<BR/>Tolerability<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Patients completing 5 days of treatment were "evaluable". No patients developed proven fungal infection. Not clear how many died</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Savino-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: sealed envelopes drawn sequentially<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>147 critically ill surgical and trauma patients, prophylactic<BR/>Excluded: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: nystatin 2 MIE x 4<BR/>Control: no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Data on infections and deaths were not divided on treatment groups according to our definitions. Four-armed study, with ketoconazole and clotrimazole in addition</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Tian-1997">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>80 patients with acute leukaemia and other haematologic malignancies, prophylactic<BR/>Excluded: NA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 50 mg daily<BR/>Control: nystatin 0.5 MIE x 3</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Abstract, few data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-van-Delden-1995">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>74 cancer patients with neutropenia, mostly leukaemia, prophylactic<BR/>Excluded: 1 in fluconazole group, 6 in nystatin group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 100 mg daily as capsule (iv if not tolerated)<BR/>Control: nystatin 0.8 MIE/d as solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Trial stopped prematurely because of other trial results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Young-1999">
<CHAR_METHODS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA<BR/>Blinding: double-blind (double-dummy technique)<BR/>Patients could be enrolled more than once (no data given)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>164 leukaemic patients with neutropenia after chemotherapy, prophylactic<BR/>Excluded: 1 from mortality analysis, 55 from other efficacy analyses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: fluconazole 200 mg daily<BR/>Control: nystatin 6 MIE daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Colonisation<BR/>Infections<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>The validity of this trial is greatly reduced by the many exclusions, some of which appear rather dubious, eg 12 versus 0 patients were excluded because of "incorrect dosing" although all patients recieved the same doses because of the double-dummy technique. Intention-to-treat analysis rendered significant findings non-significant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>NA: not available</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Carpentieri-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-DeGregorio-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Epstein-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>All 40 patients received systemic fluconazole, 200 mg/d, which is an effective treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Hoppe-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>Failed because of serious compliance problems</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Williams-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<P>No relevant data, only "Candida-free days"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-07 14:13:18 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Buchanan-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Egger-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ellis-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feusner-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Flynn-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Groll-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lumbreras-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pons-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Powles-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Savino-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tian-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Young-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Delden-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-08-07 14:13:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:11:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buchanan-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:12:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Egger-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Feusner-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:12:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flynn-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:12:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Groll-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:12:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lumbreras-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:12:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pons-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Powles-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:13:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Savino-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:13:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Delden-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE>Harms</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Experimental drug</P>
</TH>
<TH>
<P>Control</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>Harms</P>
</TH>
</TR>
<TR>
<TD>
<P>Epstein 1992</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>saline</P>
</TD>
<TD>
<P>50 versus 36</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Savino 1994</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>none</P>
</TD>
<TD>
<P>75 versus 72</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Buchanan 1985</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>39 versus 39</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Egger 1995</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>46 versus 43</P>
</TD>
<TD>
<P>Treatment discontinuations: 3 (poor tolerance and severe vomiting) versus 1 (rising liver enzymes). Oral administration of nystatin was difficult in patients receiving therapy for more than 2 weeks</P>
</TD>
</TR>
<TR>
<TD>
<P>Ellis 1994</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>48 versus 42</P>
</TD>
<TD>
<P>Treatment discontinuations: none for more than one day at the time; Nausea: 3 versus 0; Severe calf cramps: 0 versus 1. Several patients had difficulties in sucking the trouches due to mucositis. More patients on fluconazole had minor bilirubin changes; mean increases in liver enzymes similar in the two groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Feusner 1994</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>178 total</P>
</TD>
<TD>
<P>Treatment discontinuations: 0 versus 5 (1 seizure, 2 vomiting, 1 nausea, 1 rash); Other harms: 21 versus 25 (mostly gastrointestinal)</P>
</TD>
</TR>
<TR>
<TD>
<P>Flynn 1995</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>88 versus 94</P>
</TD>
<TD>
<P>Treatment discontinuations: 0 versus 2 (gastrointestinal effects); "Clinical side effects thought to be related to treatment": 3 versus 7 (mostly gastrointestinal); Liver function test abnormalities: 7% versus 8%</P>
</TD>
</TR>
<TR>
<TD>
<P>Groll 1997</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>25 versus 25</P>
</TD>
<TD>
<P>Treatment discontinuations: none; Nausea and gastrointestinal discomfort: 0 versus 3; Pruritus: 0 versus 1; Elevated liver enzymes: 3 versus 7</P>
</TD>
</TR>
<TR>
<TD>
<P>Lumbreras 1996</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>67 versus 76</P>
</TD>
<TD>
<P>Treatment discontinuations: 0 versus 1 (confusion); Adverse events ascribed to drugs: 25% versus 33%; Mild gastrointestinal symptoms: 19% versus 9%; Acute renal failure: 12% versus 13%; Liver enzymes: "no differences" (no data)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pons 1997</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>84 versus 83</P>
</TD>
<TD>
<P>Treatment discontinuations: 2 versus 3 (adverse effects or abnormal laboratory values, including 1 vomiting versus 1 nausea and 1 liver enzymes increase); Other harms: no data</P>
</TD>
</TR>
<TR>
<TD>
<P>Tian 1997</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>40 versus 40</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>van Delden 1995</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>33 versus 36</P>
</TD>
<TD>
<P>Treatment discontinuations: 4 (1 mucositis, 1 rash, 1 vomiting) versus 0; Rash: 3 versus 6<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Young 1999</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>78 versus 86</P>
</TD>
<TD>
<P>Treatment discontinuations: 11 versus 6 (reasons not specified, most common were gastrointestinal adverse effects); Liver enzyme increase: 19 versus 7; Other harms: similar (extensive table on harms)</P>
</TD>
</TR>
<TR>
<TD>
<P>Powles 1999</P>
</TD>
<TD>
<P>nystatin</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>16 versus 15</P>
</TD>
<TD>
<P>Treatment discontinuations: 6 versus 3; Infusion related toxicity: 15 versus 10; Renal impairment: 0 vs 3; Liver dysfunction: 0 versus 2</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NO="1">
<NAME>Nystatin versus placebo</NAME>
<DICH_OUTCOME CHI2="0.09220652720900471" CI_END="1.1307201852950097" CI_START="0.6454810590072871" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.854317542044607" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.053355145139985134" LOG_CI_START="-0.19011649714551931" LOG_EFFECT_SIZE="-0.06838067600276711" METHOD="MH" NO="1" P_CHI2="0.9549433478773813" P_Q="1.0" P_Z="0.27092340646375346" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="147" WEIGHT="100.0" Z="1.1009385811491301">
<NAME>Colonisation</NAME>
<GROUP_LABEL_1>Nystatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nystatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.229708187101017" CI_START="0.6425292317950689" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.08980206447387924" LOG_CI_START="-0.1921071093686419" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="1" O_E="0.0" SE="0.16559484418801332" STUDY_ID="STD-Buchanan-1985" TOTAL_1="39" TOTAL_2="39" VAR="0.027421652421652412" WEIGHT="45.62471428915141"/>
<DICH_DATA CI_END="1.6780884332401238" CI_START="0.4314708728393512" EFFECT_SIZE="0.850909090909091" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.2248148438920903" LOG_CI_START="-0.3650485167323299" LOG_EFFECT_SIZE="-0.07011683642011979" ORDER="2" O_E="0.0" SE="0.3464886579015106" STUDY_ID="STD-Epstein-1992" TOTAL_1="50" TOTAL_2="36" VAR="0.12005439005439007" WEIGHT="21.613775072380083"/>
<DICH_DATA CI_END="1.4454887607896156" CI_START="0.4521270701412742" EFFECT_SIZE="0.8084210526315789" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.16001471921938706" LOG_CI_START="-0.34473948973405866" LOG_EFFECT_SIZE="-0.09236238525733578" ORDER="3" O_E="0.0" SE="0.2964951209128848" STUDY_ID="STD-Savino-1994" TOTAL_1="75" TOTAL_2="72" VAR="0.08790935672514619" WEIGHT="32.761510638468515"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-09-03 12:04:24 +0100" MODIFIED_BY="Clare Jess" NO="2">
<NAME>Fluconazole versus nystatin</NAME>
<DICH_OUTCOME CHI2="24.807003186255503" CI_END="0.6845640831535138" CI_START="0.3609614647166388" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49709280234931513" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="233" I2="67.75104215557784" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.16458589061653214" LOG_CI_START="-0.44253915974037483" LOG_EFFECT_SIZE="-0.3035625251784535" METHOD="MH" NO="1" P_CHI2="0.0016760202823404846" P_Q="1.0" P_Z="1.859793001645982E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13990453175743178" TOTALS="YES" TOTAL_1="487" TOTAL_2="460" WEIGHT="100.0" Z="4.28109097821556">
<NAME>Colonisation</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Nystatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nystatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3052965905896727" CI_START="0.3670769175217845" EFFECT_SIZE="0.6922024623803009" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.11570920364478157" LOG_CI_START="-0.4352429238809044" LOG_EFFECT_SIZE="-0.15976686011806138" ORDER="4" O_E="0.0" SE="0.3236320069656038" STUDY_ID="STD-Egger-1995" TOTAL_1="43" TOTAL_2="46" VAR="0.10473767593258464" WEIGHT="10.896509189442332"/>
<DICH_DATA CI_END="0.9832286477706538" CI_START="0.3038498794524431" EFFECT_SIZE="0.546583850931677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="-0.007345476147374737" LOG_CI_START="-0.5173409316159874" LOG_EFFECT_SIZE="-0.26234320388168103" ORDER="5" O_E="0.0" SE="0.2995738550604825" STUDY_ID="STD-Ellis-1994" TOTAL_1="42" TOTAL_2="48" VAR="0.08974449463579899" WEIGHT="11.607913632758601"/>
<DICH_DATA CI_END="1.14994193074312" CI_START="0.0038649294591530706" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0606759100974609" LOG_CI_START="-2.4128584282088235" LOG_EFFECT_SIZE="-1.1760912590556813" ORDER="6" O_E="0.0" SE="1.4529663145135578" STUDY_ID="STD-Feusner-1994" TOTAL_1="89" TOTAL_2="89" VAR="2.111111111111111" WEIGHT="1.1842414656979796"/>
<DICH_DATA CI_END="0.40671867563180647" CI_START="0.17347774973793775" EFFECT_SIZE="0.265625" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="48" LOG_CI_END="-0.39070588528505246" LOG_CI_START="-0.760756219926174" LOG_EFFECT_SIZE="-0.5757310526056132" ORDER="7" O_E="0.0" SE="0.21736939834689387" STUDY_ID="STD-Flynn-1995" TOTAL_1="72" TOTAL_2="54" VAR="0.04724945533769062" WEIGHT="14.243597508103516"/>
<DICH_DATA CI_END="1.2666625184843185" CI_START="0.6320183986958399" EFFECT_SIZE="0.8947368421052632" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.10266091963215801" LOG_CI_START="-0.19927027878126805" LOG_EFFECT_SIZE="-0.04830467957455503" ORDER="8" O_E="0.0" SE="0.17735588053158297" STUDY_ID="STD-Groll-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.03145510835913313" WEIGHT="15.556440608806065"/>
<DICH_DATA CI_END="0.7518467300205326" CI_START="0.30462407176878087" EFFECT_SIZE="0.4785714285714286" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="35" LOG_CI_END="-0.1238706847949225" LOG_CI_START="-0.5162357811599008" LOG_EFFECT_SIZE="-0.32005323297741156" ORDER="9" O_E="0.0" SE="0.23047719984333923" STUDY_ID="STD-Lumbreras-1996" TOTAL_1="76" TOTAL_2="67" VAR="0.05311973964762652" WEIGHT="13.810418994540322"/>
<DICH_DATA CI_END="0.5701137960423015" CI_START="0.31336655591813267" EFFECT_SIZE="0.42267552182163187" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="62" LOG_CI_END="-0.2440384494842927" LOG_CI_START="-0.5039473555229759" LOG_EFFECT_SIZE="-0.3739929025036342" ORDER="10" O_E="0.0" SE="0.15267177797695689" STUDY_ID="STD-Pons-1997" TOTAL_1="68" TOTAL_2="66" VAR="0.02330867179064522" WEIGHT="16.332906935648047"/>
<DICH_DATA CI_END="1.1895103873062616" CI_START="0.17369463306312252" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.07536823883238093" LOG_CI_START="-0.7602136004767934" LOG_EFFECT_SIZE="-0.3424226808222062" ORDER="11" O_E="0.0" SE="0.4908249086070214" STUDY_ID="STD-Tian-1997" TOTAL_1="40" TOTAL_2="40" VAR="0.24090909090909088" WEIGHT="7.000133150578254"/>
<DICH_DATA CI_END="1.197385434505019" CI_START="0.26961291594953307" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.07823397090289254" LOG_CI_START="-0.569259306531192" LOG_EFFECT_SIZE="-0.2455126678141498" ORDER="12" O_E="0.0" SE="0.38034075630819647" STUDY_ID="STD-van-Delden-1995" TOTAL_1="32" TOTAL_2="25" VAR="0.1446590909090909" WEIGHT="9.367838514424891"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7596399574083357" CI_END="0.9314062392876816" CI_START="0.16758806596033732" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3950855227233892" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.03086085714933074" LOG_CI_START="-0.775756910956972" LOG_EFFECT_SIZE="-0.4033088840531514" METHOD="MH" NO="2" P_CHI2="0.7369828287013583" P_Q="1.0" P_Z="0.03380704696023925" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="311" TOTAL_2="306" WEIGHT="100.0" Z="2.1223656196018594">
<NAME>Fungal invasion</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Nystatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nystatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.688650380565166" CI_START="0.05029322875837325" EFFECT_SIZE="0.5348837209302325" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7550092432321541" LOG_CI_START="-1.2984904823561414" LOG_EFFECT_SIZE="-0.2717406195619937" ORDER="13" O_E="0.0" SE="1.2062359037981454" STUDY_ID="STD-Egger-1995" TOTAL_1="43" TOTAL_2="46" VAR="1.4550050556117289" WEIGHT="10.861918135178476"/>
<DICH_DATA CI_END="1.4868936069940297" CI_START="0.07170804974310176" EFFECT_SIZE="0.32653061224489793" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.1722798941786643" LOG_CI_START="-1.1444320889238422" LOG_EFFECT_SIZE="-0.4860760973725889" ORDER="14" O_E="0.0" SE="0.7734431367038469" STUDY_ID="STD-Ellis-1994" TOTAL_1="42" TOTAL_2="48" VAR="0.5982142857142856" WEIGHT="36.720019370165375"/>
<DICH_DATA CI_END="2.7260053772752886" CI_START="0.007486472123435282" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4355267081819571" LOG_CI_START="-2.125722788210471" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="15" O_E="0.0" SE="1.5044906325703937" STUDY_ID="STD-Feusner-1994" TOTAL_1="89" TOTAL_2="89" VAR="2.2634920634920634" WEIGHT="19.671438948302878"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="16" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Groll-1997" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="2.8102055640432684"/>
<DICH_DATA CI_END="1.9236334498929455" CI_START="0.02525108930207263" EFFECT_SIZE="0.22039473684210525" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.28412232037599533" LOG_CI_START="-1.59771988219185" LOG_EFFECT_SIZE="-0.6567987809079273" ORDER="17" O_E="0.0" SE="1.1054034250574898" STUDY_ID="STD-Lumbreras-1996" TOTAL_1="76" TOTAL_2="67" VAR="1.2219167321288296" WEIGHT="23.896573187948352"/>
<DICH_DATA CI_END="13.20185019913503" CI_START="0.05616730492272936" EFFECT_SIZE="0.8611111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1206348005214486" LOG_CI_START="-1.2505164143874776" LOG_EFFECT_SIZE="-0.06494080693301456" ORDER="18" O_E="0.0" SE="1.3928259610253153" STUDY_ID="STD-van-Delden-1995" TOTAL_1="36" TOTAL_2="31" VAR="1.9399641577060933" WEIGHT="6.039844794361652"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.083206618956215" CI_END="1.034462507737322" CI_START="0.5400614710119775" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.74744454218046" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.014714755052154473" LOG_CI_START="-0.2675568049883053" LOG_EFFECT_SIZE="-0.12642102496807536" METHOD="MH" NO="3" P_CHI2="0.537499659301065" P_Q="1.0" P_Z="0.07915348718104505" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="357" TOTAL_2="335" WEIGHT="100.00000000000001" Z="1.7556189918003127">
<NAME>Death</NAME>
<GROUP_LABEL_1>Fluconazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Nystatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fluconazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nystatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1173523374951875" CI_START="0.25886651873574756" EFFECT_SIZE="0.5378151260504201" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.04819014187262024" LOG_CI_START="-0.5869241166899075" LOG_EFFECT_SIZE="-0.2693669874086436" ORDER="19" O_E="0.0" SE="0.3730692593459123" STUDY_ID="STD-Ellis-1994" TOTAL_1="42" TOTAL_2="48" VAR="0.13918067226890757" WEIGHT="27.028693429633723"/>
<DICH_DATA CI_END="96.23209281693097" CI_START="0.22800946765845678" EFFECT_SIZE="4.684210526315789" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9833199307589031" LOG_CI_START="-0.6420471193747356" LOG_EFFECT_SIZE="0.6706364056920838" ORDER="20" O_E="0.0" SE="1.5421536010249908" STUDY_ID="STD-Flynn-1995" TOTAL_1="94" TOTAL_2="88" VAR="2.3782377291543466" WEIGHT="0.8795188193557738"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="21" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Groll-1997" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.8517445408498021"/>
<DICH_DATA CI_END="2.2655708436576223" CI_START="0.42350618277617413" EFFECT_SIZE="0.97953216374269" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3551776469736204" LOG_CI_START="-0.37314024501220006" LOG_EFFECT_SIZE="-0.008981299019289804" ORDER="22" O_E="0.0" SE="0.4278175349841807" STUDY_ID="STD-Lumbreras-1996" TOTAL_1="76" TOTAL_2="67" VAR="0.18302784323994065" WEIGHT="16.296315131224187"/>
<DICH_DATA CI_END="1.1903714669685346" CI_START="0.5176249565407335" EFFECT_SIZE="0.7849624060150376" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.07568250835080356" LOG_CI_START="-0.28598479295248835" LOG_EFFECT_SIZE="-0.10515114230084241" ORDER="23" O_E="0.0" SE="0.21244516306756844" STUDY_ID="STD-van-Delden-1995" TOTAL_1="35" TOTAL_2="29" VAR="0.04513294731080575" WEIGHT="35.4006324790699"/>
<DICH_DATA CI_END="1.2891442358564271" CI_START="0.19434213671166134" EFFECT_SIZE="0.5005347593582887" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.11030151109438388" LOG_CI_START="-0.7114330266911715" LOG_EFFECT_SIZE="-0.3005657577983938" ORDER="24" O_E="0.0" SE="0.4826909351467995" STUDY_ID="STD-Young-1999" TOTAL_1="85" TOTAL_2="78" VAR="0.23299053887289178" WEIGHT="19.543095599866625"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-09-27 16:25:36 +0100" MODIFIED_BY="Clare Jess">
<APPENDIX ID="APP-01" MODIFIED="2011-09-27 16:25:36 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2011-09-27 16:25:36 +0100" MODIFIED_BY="Clare Jess">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-27 16:25:36 +0100" MODIFIED_BY="Clare Jess">
<P>#1: random* OR control* OR blind*<BR/>#2: nystatin OR amphotericin OR fluconazol* OR itraconazol* OR ketoconazol* OR miconazol* OR voriconazol*<BR/>#3: bone-marrow OR cancer* OR fungemia OR hematologic* OR malignan* OR neoplas* OR neutropeni* OR granulocytopeni* OR leukemi* OR lymphom*<BR/>#4: #1 AND #2 AND #3.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>